Entrada Therapeutics holder reports 9.98% stake

Rhea-AI Filing Summary

Entrada Therapeutics, Inc. reports that a group of MPM BioVentures funds and related entities, together with Ansbert Gadicke, Luke Evnin and Todd Foley, collectively beneficially own 3,885,115 shares of common stock, representing 9.98% of the outstanding shares as of July 31, 2026.

The shares are held across several Delaware limited partnerships and LLCs, including BV 2014, BV 2014(B), AM BV2014 LLC, BV 2018, BV 2018(B) and AM BV2018 LLC, with associated GP and management entities deemed to share voting and dispositive power. The amendment is dated September 8, 2026 and notes that individual percentage figures in the cover tables are rounded to 9.9% due to EDGAR field limits.

Key Figures

Beneficial ownership shares: 3,885,115 shares Beneficial ownership percentage: 9.98% Shares outstanding: 38,936,669 shares +5 more

8 metrics

Beneficial ownership shares 3,885,115 shares Common stock of Entrada Therapeutics beneficially owned by the MPM group and listed persons

Beneficial ownership percentage 9.98% Portion of Entrada Therapeutics common stock beneficially owned by Drs. Gadicke and Evnin and Mr. Foley with related entities

Shares outstanding 38,936,669 shares Entrada Therapeutics common stock outstanding as of July 31, 2026 used for ownership calculations

BV 2014 holding 1,764,167 shares Shares of Entrada Therapeutics common stock held directly by MPM BioVentures 2014, L.P.

BV 2018 holding 1,810,592 shares Shares of Entrada Therapeutics common stock held directly by MPM BioVentures 2018, L.P.

BV 2014 LLC deemed ownership 1,942,556 shares Aggregate amount beneficially owned by MPM BioVentures 2014 LLC as reported

BV 2018 LLC deemed ownership 1,942,559 shares Aggregate amount beneficially owned by MPM BioVentures 2018 LLC as reported

Individual reported percentage per person 9.9% Rounded percentage of class shown for each of Gadicke, Evnin and Foley due to EDGAR limits

Key Terms

beneficially own, Schedule 13D, sole voting power, shared dispositive power, +1 more

5 terms

beneficially own financial

"percentages of the shares of Common Stock beneficially owned by the Filing Person"

Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.

Schedule 13D regulatory

"previously filed a statement on Schedule 13G to report the acquisition"

A Schedule 13D is a legal document that investors file with regulators when they buy a large enough stake in a company to potentially influence its management or decisions. It provides details about the investor’s intention, ownership stake, and plans, helping other investors understand who is gaining control and what their motives might be.

sole voting power financial

"Number of Shares Beneficially Owned by Each Reporting Person With: | 7 | Sole Voting Power"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

shared dispositive power financial

"Number of Shares Beneficially Owned by Each Reporting Person With: ... Shared Dispositive Power"

venture capital investment business financial

"The principal business of each of the Filing Persons is the venture capital investment business"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What ownership stake in TRDA does the MPM group report in this Schedule 13D/A?

The filing states that Ansbert Gadicke, Luke Evnin and Todd Foley, together with related MPM entities, beneficially own 3,885,115 TRDA shares, representing 9.98% of Entrada Therapeutics’ common stock, based on 38,936,669 shares outstanding as of July 31, 2026.

How many Entrada Therapeutics (TRDA) shares do the main MPM 2014 funds hold?

The filing reports that BV 2014 holds 1,764,167 shares and BV 2014(B) holds 117,667 shares of Entrada Therapeutics common stock. AM BV2014 LLC holds an additional 60,722 shares, with related GP and management entities deemed to beneficially own these holdings.

How many Entrada Therapeutics (TRDA) shares do the MPM 2018 funds hold?

The document states that BV 2018 holds 1,810,592 shares, BV 2018(B) holds 96,232 shares, and AM BV2018 LLC holds 35,735 shares of TRDA common stock, with related GP and management entities deemed to beneficially own these shares.

What percentage of Entrada Therapeutics (TRDA) is used to calculate the MPM group’s ownership?

Percentages are calculated using 38,936,669 shares of Entrada Therapeutics common stock outstanding as of July 31, 2026, as reported in the company’s Form 10‑Q filed on August 5, 2026.

Why does the filing show 9.9% for some TRDA reporting persons when the group owns 9.98%?

The filing explains that Drs. Gadicke and Evnin and Mr. Foley beneficially own 9.98% of TRDA common stock, but the percentages in the cover page rows are rounded to 9.9% due to field limitations of the SEC’s EDGAR filing system.

Did the reporting persons disclose any recent trading in TRDA shares?

The filing states that, except as set forth in Exhibit 99.2 (Trade Details), the reporting persons have not effected any transactions in Entrada Therapeutics common stock in the sixty days preceding the date of the statement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/10/2026 - 04:27 PM Accepted by SEC EDGAR 09/10/2026 - 04:26 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 1)

ENTRADA THERAPEUTICS, INC.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

29384C108

(CUSIP Number)

Ansbert Gadicke
c/o MPM BioImpact LLC, 339 Boylston Street, Suite 1100
Boston, MA, 02116
617-425-9200

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

09/08/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): 29384C108

1

Name of reporting person

MPM BioVentures 2014, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 1,764,167.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 1,764,167.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

1,764,167.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

4.5 %

14

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13D

CUSIP Number(s): 29384C108

1

Name of reporting person

MPM BioVentures 2014 (B), L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 117,667.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 117,667.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

117,667.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.3 %

14

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13D

CUSIP Number(s): 29384C108

1

Name of reporting person

MPM Asset Management Investors BV2014 LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 60,722.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 60,722.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

60,722.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.2 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

CUSIP Number(s): 29384C108

1

Name of reporting person

MPM BioVentures 2014 GP LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,881,834.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,881,834.00

11

Aggregate amount beneficially owned by each reporting person

1,881,834.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

4.8 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

CUSIP Number(s): 29384C108

1

Name of reporting person

MPM BioVentures 2014 LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,942,556.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,942,556.00

11

Aggregate amount beneficially owned by each reporting person

1,942,556.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

5.0 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

CUSIP Number(s): 29384C108

1

Name of reporting person

MPM BIOVENTURES 2018, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 1,810,592.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 1,810,592.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

1,810,592.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

4.7 %

14

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13D

CUSIP Number(s): 29384C108

1

Name of reporting person

MPM BIOVENTURES 2018 (B), L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 96,232.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 96,232.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

96,232.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.2 %

14

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13D

CUSIP Number(s): 29384C108

1

Name of reporting person

MPM ASSET MANAGEMENT INVESTORS BV2018 LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 35,735.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 35,735.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

35,735.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.1 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

CUSIP Number(s): 29384C108

1

Name of reporting person

MPM BioVentures 2018 GP LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,906,824.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,906,824.00

11

Aggregate amount beneficially owned by each reporting person

1,906,824.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

4.9 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

CUSIP Number(s): 29384C108

1

Name of reporting person

MPM BioVentures 2018 LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,942,559.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,942,559.00

11

Aggregate amount beneficially owned by each reporting person

1,942,559.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

5.0 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

CUSIP Number(s): 29384C108

1

Name of reporting person

ANSBERT GADICKE

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 3,885,115.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 3,885,115.00

11

Aggregate amount beneficially owned by each reporting person

3,885,115.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

9.9 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

CUSIP Number(s): 29384C108

1

Name of reporting person

LUKE EVNIN

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 3,885,115.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 3,885,115.00

11

Aggregate amount beneficially owned by each reporting person

3,885,115.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

9.9 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

CUSIP Number(s): 29384C108

1

Name of reporting person

Todd Foley

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 3,885,115.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 3,885,115.00

11

Aggregate amount beneficially owned by each reporting person

3,885,115.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

9.9 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock
(b)	Name of Issuer: ENTRADA THERAPEUTICS, INC.
(c)	Address of Issuer's Principal Executive Offices: ONE DESIGN CENTER PLACE, SUITE 17-500, BOSTON, MASSACHUSETTS , 02210.
Item 1 Comment: Explanatory Note: This Amendment No. 1 to Schedule 13D ("Amendment No. 1") is being filed as an amendment to the initial statement on Schedule 13D relating to the common stock (the "Common Stock"), of Entrada Therapeutics, Inc. (the 'Issuer'), as filed with the Securities and Exchange Commission (the "SEC") on November 12, 2021 (as amended, the "Original Schedule 13D"). This Schedule 13D/A is being filed by the Filing Persons to report the open market sales of the Issuer's Common Stock by certain Filing Persons. Items 2, 5 and 7 of the Original Schedule 13D are hereby amended and supplemented to the extent hereinafter expressly set forth and, except as amended and supplemented hereby, the Original Schedule 13D remains in full force and effect. All capitalized terms used in this Amendment No. 1 but not defined herein shall have the meanings ascribed thereto in the Original Schedule 13D.
Item 2.	Identity and Background
(a)	The entities and persons filing this statement are MPM BioVentures 2014, L.P. ("BV 2014"), MPM BioVentures 2014 (B), L.P. ("BV 2014(B)"), MPM Asset Management Investors BV2014 LLC ("AM BV2014 LLC"), MPM BioVentures 2018, L.P. ("BV 2018"), MPM BioVentures 2018 (B), L.P. ("BV 2018(B)"), MPM Asset Management Investors BV2018 LLC ("AM BV2018 LLC"), MPM BioVentures 2014 GP LLC ("BV 2014 GP"), MPM BioVentures 2014 LLC ("BV 2014 LLC"), MPM BioVentures 2018 GP LLC ("BV 2018 GP") and MPM BioVentures 2018 LLC ("BV 2018 LLC") (collectively, the "MPM Entities") and Ansbert Gadicke, Luke Evnin and Todd Foley (collectively, the "Listed Persons" and together with the MPM Entities, the "Filing Persons").
(b)	The address of the principal place of business for each of the MPM Entities and Ansbert Gadicke, Luke Evnin and Todd Foley is 399 Boylston Street, Boston, MA 02116.
(c)	The principal business of each of the Filing Persons is the venture capital investment business.
(d)	During the last five years, none of the Filing Persons has been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors).
(e)	During the last five years, none of the Filing Persons has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
(f)	Each of the Listed Persons is a United States citizen and each of the MPM Entities is a Delaware limited partnership or limited liability company. In accordance with the provisions of General Instruction C to Schedule 13D, information concerning the managers and each other person controlling the general partners of the MPM Entities required by Item 2 of Schedule 13D is listed on Schedule 1 hereto and is incorporated by reference herein.
Item 5.	Interest in Securities of the Issuer
(a)	See rows (11) and (13) of the Filing Persons Owner Profile of this Amendment No. 1 for the aggregate number of Common Stock and percentages of the shares of Common Stock beneficially owned by the Filing Person. Drs. Gadicke and Evnin and Mr. Foley beneficially own 9.98% of the Common Stock as of the date of this filing, and due to field limitations of the SEC's EDGAR filing system, the percentages in row 11 for each of these Reporting Persons has been rounded to 9.9%. The Common Stock is held as follows: * 1,764,167 shares are held directly by BV 2014; * 117,667 shares are held directly by BV 2014(B); * 60,722 shares are held directly by AM BV2014 LLC; * 1,810,592 shares are held directly by BV 2018; * 96,232 shares are held directly by BV 2018(B); and * 35,735 shares are held directly by AM BV2018 LLC. BV 2014 GP and BV 2014 LLC are the direct and indirect general partners of BV 2014 and BV 2014(B) and, accordingly, may be deemed to beneficially own the shares held by BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014 LLC and, accordingly, may be deemed to beneficially own the shares held by AM BV2014 LLC. BV 2018 GP and BV 2018 LLC are the direct and indirect general partners of BV 2018 and BV 2018(B) and, accordingly, may be deemed to beneficially own the shares held by BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018 LLC and, accordingly, may be deemed to beneficially own the shares held by AM BV2018 LLC. Drs. Gadicke and Evnin and Mr. Foley are the managing directors of BV 2014 LLC and BV 2018 LLC and, accordingly, may be deemed to beneficially own the shares held by BV 2014, BV 2014(B), AM BV2014 LLC, BV 2018, BV 2018(B) and AM BV2018 LLC. Calculation of the percentage of the shares of Common Stock beneficially owned is based upon 38,936,669 Common Stock outstanding as of July 31, 2026, as reported in the Issuer's Form 10-Q filed with the SEC on August 5, 2026.
(b)	See rows (7) through (10) of the Filing Persons Owner Profile of this Amendment No. 1 for the number of shares as to which there is sole power to vote or to direct the vote, sole power to dispose or to direct the disposition, or shared power to dispose or to direct the disposition.
(c)	Except as set forth in Exhibit 99.2, the Reporting Persons have not effected any transactions in the Common Stock in the sixty days preceding the date of this filing.
(d)	Inapplicable.
(e)	Inapplicable.
Item 7.	Material to be Filed as Exhibits.
	Exhibit 1 Schedule I Exhibit 99.1 Joint Filing Statement Exhibit 99.2 Trade Details

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

MPM BioVentures 2014, L.P.

Signature:	/s/ Ansbert Gadicke
Name/Title:	Managing Director of MPM BioVentures 2014 LLC, the Managing Member of MPM BioVentures 2014 GP LLC, the General Partner of MPM BioVentures 2014, L.P.
Date:	09/10/2026

MPM BioVentures 2014 (B), L.P.

Signature:	/s/ Ansbert Gadicke
Name/Title:	Managing Director of MPM BioVentures 2014 LLC, Managing Member of MPM BioVentures 2014 GP LLC, the General Partner of MPM BioVentures 2014 (B), L.P.
Date:	09/10/2026

MPM Asset Management Investors BV2014 LLC

Signature:	/s/ Ansbert Gadicke
Name/Title:	Managing Director of MPM BioVentures 2014 LLC, the manager of MPM Asset Management Investors BV2014 LLC
Date:	09/10/2026

MPM BioVentures 2014 GP LLC

Signature:	/s/ Ansbert Gadicke
Name/Title:	Managing Director of MPM BioVentures 2014 LLC, the Managing Member of MPM BioVentures 2014 GP LLC
Date:	09/10/2026

MPM BioVentures 2014 LLC

Signature:	/s/ Ansbert Gadicke
Name/Title:	Managing Director
Date:	09/10/2026

MPM BIOVENTURES 2018, L.P.

Signature:	/s/ Ansbert Gadicke
Name/Title:	Managing Director of MPM BioVentures 2018 LLC, the Managing Member of MPM BioVentures 2018 GP LLC, the General Partner of MPM BioVentures 2018, L.P.
Date:	09/10/2026

MPM BIOVENTURES 2018 (B), L.P.

Signature:	/s/ Ansbert Gadicke
Name/Title:	Managing Director of MPM BioVentures 2018 LLC, Managing Member of MPM BioVentures 2018 GP LLC, the General Partner of MPM BioVentures 2018 (B), L.P.
Date:	09/10/2026

MPM ASSET MANAGEMENT INVESTORS BV2018 LLC

Signature:	/s/ Ansbert Gadicke
Name/Title:	Managing Director of MPM BioVentures 2018 LLC, the manager of MPM Asset Management Investors BV2018 LLC
Date:	09/10/2026

MPM BioVentures 2018 GP LLC

Signature:	/s/ Ansbert Gadicke
Name/Title:	Managing Director of MPM BioVentures 2018 LLC, the Managing Member of MPM BioVentures 2018 GP LLC
Date:	09/10/2026

MPM BioVentures 2018 LLC

Signature:	/s/ Ansbert Gadicke
Name/Title:	Managing Director
Date:	09/10/2026

ANSBERT GADICKE

Signature:	/s/ Ansbert Gadicke
Name/Title:	Ansbert Gadicke
Date:	09/10/2026

LUKE EVNIN

Signature:	/s/ Luke Evnin
Name/Title:	Luke Evnin
Date:	09/10/2026

Todd Foley

Signature:	/s/ Todd Foley
Name/Title:	Todd Foley
Date:	09/10/2026